Abstract
HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.
| Original language | English |
|---|---|
| Pages (from-to) | 14192-14220 |
| Number of pages | 29 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Keywords
- Cholangiocarcinoma
- Hepatocellular carcinoma
- Metastasis
- Prognosis
- Serum markers
- Tissue markers
ASJC Scopus subject areas
- Oncology
Cite this
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma : Clinical and prognostic implications. / Berretta, Massimiliano; Cavaliere, Carla; Alessandrini, Lara; Stanzione, Brigida; Facchini, Gaetano; Balestreri, Luca; Perin, Tiziana; Canzonieri, Vincenzo.
In: Oncotarget, Vol. 8, No. 8, 2017, p. 14192-14220.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma
T2 - Clinical and prognostic implications
AU - Berretta, Massimiliano
AU - Cavaliere, Carla
AU - Alessandrini, Lara
AU - Stanzione, Brigida
AU - Facchini, Gaetano
AU - Balestreri, Luca
AU - Perin, Tiziana
AU - Canzonieri, Vincenzo
PY - 2017
Y1 - 2017
N2 - HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.
AB - HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.
KW - Cholangiocarcinoma
KW - Hepatocellular carcinoma
KW - Metastasis
KW - Prognosis
KW - Serum markers
KW - Tissue markers
UR - http://www.scopus.com/inward/record.url?scp=85013392545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013392545&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.13929
DO - 10.18632/oncotarget.13929
M3 - Review article
VL - 8
SP - 14192
EP - 14220
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 8
ER -